Immutep Ltd
NASDAQ:IMMP

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
NASDAQ:IMMP
Watchlist
Price: 3.08 USD 4.41% Market Closed
Market Cap: 447.4m USD

Intrinsic Value

The intrinsic value of one IMMP stock under the Base Case scenario is 18.56 USD. Compared to the current market price of 3.08 USD, Immutep Ltd is Undervalued by 83%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMMP Intrinsic Value
18.56 USD
Undervaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Immutep Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about IMMP?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is IMMP valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Immutep Ltd.

Explain Valuation
Compare IMMP to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Delays or failures in Immutep’s lead product candidate eftilagimod alpha could undermine its pipeline credibility, especially given the high stakes of LAG-3–targeted therapies and the company’s limited clinical-stage assets.

A high cash burn rate relative to Immutep’s available funding threatens near-term liquidity, raising concerns that additional capital raises or dilutive share issuances may be necessary to sustain operations.

Intensifying competition in the LAG-3 immunotherapy space from larger biotech and pharmaceutical players puts pressure on Immutep’s ability to differentiate its treatments and secure favorable partnership terms.

Bull Theses

Eftilagimod alpha’s encouraging clinical data in combination with checkpoint inhibitors suggests a strong potential to become a new standard in immuno-oncology, particularly for challenging cancers like metastatic breast cancer.

Multiple partnerships and licensing agreements with established pharmaceutical companies like Merck provide Immutep with both external validation and a path to milestone payments that could support long-term development efforts.

An expanding pipeline of LAG-3–focused candidates beyond eftilagimod alpha leverages Immutep’s deep expertise in immuno-oncology, potentially positioning the company at the forefront of next-generation cancer treatments.

Show More Less
How do you feel about IMM?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immutep Ltd

Current Assets 149.1m
Cash & Short-Term Investments 129.7m
Receivables 10.9m
Other Current Assets 8.5m
Non-Current Assets 7.9m
PP&E 569.5k
Intangibles 7.2m
Other Non-Current Assets 116.5k
Current Liabilities 12.8m
Accounts Payable 5.5m
Accrued Liabilities 814k
Other Current Liabilities 6.4m
Non-Current Liabilities 589.3k
Long-Term Debt 314.9k
Other Non-Current Liabilities 274.4k
Efficiency

Free Cash Flow Analysis
Immutep Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Immutep Ltd

Revenue
60.1k AUD
Operating Expenses
-70.2m AUD
Operating Income
-70.1m AUD
Other Expenses
8.7m AUD
Net Income
-61.4m AUD
Fundamental Scores

IMMP Profitability Score
Profitability Due Diligence

Immutep Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

13/100
Profitability
Score

Immutep Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

IMMP Solvency Score
Solvency Due Diligence

Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMMP Price Targets Summary
Immutep Ltd

Wall Street analysts forecast IMMP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMMP is 3.3 USD with a low forecast of 2.79 USD and a high forecast of 4.01 USD.

Lowest
Price Target
2.79 USD
9% Downside
Average
Price Target
3.3 USD
7% Upside
Highest
Price Target
4.01 USD
30% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Immutep Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for IMM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one IMMP stock?

The intrinsic value of one IMMP stock under the Base Case scenario is 18.56 USD.

Is IMMP stock undervalued or overvalued?

Compared to the current market price of 3.08 USD, Immutep Ltd is Undervalued by 83%.

Back to Top